Has Kenneth Beer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $63,267 in general payments to Kenneth Beer, MD across 240 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kenneth Beer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kenneth Beer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kenneth Beer, MD

Dermatology · West Palm Beach, FLNPI 1699764993

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $58,635 of the $63,267 with a category attached, or 92.7%. AbbVie accounts for 66.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $20,991 and has fallen 95.0% since, to $1,047 in 2025. Among dermatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,267in general payments, 2019–2025

Across 240 payments — averaging $263.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$42K
Galderma Laboratories, L.p.$19K
Revance Therapeutics, Inc.$227
Incyte Corporation$191
Merz North America, Inc.$168
Sanofi$147
plus $1K from 21 others

$1,756,002in research payments, 2019–2025

Across 212 payments — averaging $8283.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1.3M
Merz North America, Inc.$200K
Bausch Health US, LLC$131K
LEO Pharma AS$57K
Incyte Corporation$26K
Eli Lilly$6K
plus $8K from 2 others

What the payments were for

Consulting fees$58,63593%
Food & beverage$4,6247%
Education$80%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	103	$42,027
Galderma Laboratories, L.p.	69	$19,454
Revance Therapeutics, Inc.	2	$227
Incyte Corporation	9	$191
Merz North America, Inc.	7	$168
Sanofi	1	$147
Boehringer Ingelheim	6	$147
LEO Pharma Inc.	8	$143
Regeneron Healthcare Solutions, Inc.	5	$134
Organogenesis Inc.	4	$93
Solta Medical, A Division Of Bausch Health US, LLC	4	$87
Novartis	2	$51
Amgen	2	$45
Bausch Health US, LLC	1	$45
Biofrontera Inc.	2	$42
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$39
Pfizer	2	$34
Musculoskeletal Transplant Foundation Inc.	1	$32
Strata Skin Sciences, Inc.	2	$25
UCB, Inc.	1	$22
Boston Scientific	1	$21
Sun Pharmaceutical Industries Inc.	1	$20
Almirall LLC	1	$17
Helsinn Therapeutics (U.S.), Inc.	1	$16
Sebela Pharmaceuticals Inc.	1	$16
Arcutis Biotherapeutics, Inc.	1	$16
Sensus Healthcare, Inc.	1	$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$11,638
BOTOX COSMETIC$5,258
DAXXIFY$227
DUPIXENT$147

How this compares

$63,267 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida →

Medicare billing

Part B allowed, 2024

$428,702

Medicare patients

933

Services billed

5,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	96	$2,459
Calcipotriene	13	$1,609
Fluorouracil	25	$1,419
Mometasone Furoate	63	$1,066
Tretinoin	20	$1,050
Mupirocin	85	$641
Gentamicin Sulfate	19	$494
Ketoconazole	33	$348
Minocycline Hcl	18	$334
Cephalexin	26	$239
Triamcinolone Acetonide	14	$225
Econazole Nitrate	17	$154
Ciprofloxacin Hcl	14	$144
CefuroximeCefuroxime Axetil	14	$101

Paid to pharmacies, not to this prescriber.

Other dermatology in West Palm Beach

Andrew DorizasWest Palm Beach$897K
Francisco KerdelMiami$2.1M
Brad GlickMargate$2M
Robert KirsnerMiami$1.4M
John MinniStuart$1.4M
Gil YosipovitchMiami$1M
Shino Bay AguileraFt Lauderdale$1M
Robert SnyderPembroke Pines$1M
Marc IngleseTallahassee$989K
Jeremy GreenCoral Gables$952K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →